Authors’ Disclosures
OnQuality, Cancer
ONCOLOGY, CANCER, MOORE
E.R. Kessler reports grants from Merck during the conduct of the study; grants from Bristol Myers Squibb, Seattle Genetics, Eli Lily, and AstraZeneca outside the submitted work. J. Moore reports other from Merck outside the submitted work. T.W. Flaig reports other from MERCK and Exelixis during the conduct of the study; other from Aurora Oncology outside the submitted work; in addition, T.W. Flaig has a patent to 2 patents in early stage bladder detection and treatment issued and licensed. E.T. Lam reports grants and other from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.; grants from NCI (HHS – NIH) Cancer Center Support Grant P30CA046934, Colorado Cancer Foundation, and NIH/NCI Paul Calabresi Award for Clinical Oncology Research 5K12CA086913 during the conduct of the study; grants and personal fees from Calithera Biosciences and Exelixis; grants from Advaxis, Amgen, Argos Therapeutics, Arrowhead Pharmaceuticals, Astellas Pharma, Bristol-Myers Squibb, Constellation Pharmaceuticals, Decibel Therapeutics, Forma Therapeutics, Peloton Therapeutics, Harpoon Therapeutics, OnQuality Pharmaceuticals, Pfizer, Phosplatin Therapeutics, and Genentech/Roche outside the submitted work. No disclosures were reported by the other authors.